Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23).[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.[A254716] Risankizum…